Developing combination products sounds like a strategic advantage—until the reality hits. These products combine drugs, medical devices, and/or biologics into one integrated solution, which immediately multiplies regulatory, technical, and operational complexity, as both pharmaceutical and device requirements must be met simultaneously.

Companies quickly realize that what seemed like innovation turns into confusion. Teams struggle to align across disciplines, regulatory pathways become unclear, and development timelines start slipping. The more you dig, the more urgent the question becomes: which firms specialize in combination products—and who can actually help you avoid costly mistakes.

The pressure builds fast. Misclassification alone can delay approval, while poor integration between components can introduce risks that doesn’t exist in standalone products. What starts as a promising project can stall before it ever reaches the market. That’s why success with combination products isn’t just about building something innovative—it’s about choosing the right expertise early, before complexity turns into failure.

Which firms specialize in combination products—and why complexity starts with documentation

When companies ask which firms specialize in combination products, they often underestimate one of the most critical elements behind successful combination products: documentation.

These products do not only require alignment between drug and device development—they also demand parallel regulatory evidence. In practice, this means that alongside pharmaceutical dossiers, companies must also prepare a robust medical device technical file that demonstrates compliance of the device component with EU Medical Device Regulation (MDR) requirements.

This is where complexity truly begins. The technical file must include design verification, risk management, clinical evaluation, usability data, and proof of safety and performance—all aligned with the medicinal product data.

For many teams, this becomes a bottleneck. Documentation is often developed too late or in isolation, leading to gaps that delay approval or trigger additional questions from regulators and notified bodies. What seems like a regulatory formality quickly turns into a critical risk factor.

That’s why the question which firms specialize in combination products should also include: who understands how to structure both the medicinal dossier and the medical device technical file from the start.

Because in combination products, success is not only built in the lab—it’s proven in the documentation.

How Billev Pharma East helps you succeed with combination products

When companies ask which firms specialize in combination products, they often expect a list of providers—but what they actually need is a partner who can connect every moving part of combination products into one clear path to approval. This is exactly where Billev Pharma East delivers real value.

Instead of offering isolated services, Billev Pharma East works as an integrated extension of your team, aligning development, regulatory strategy, safety, and quality into a single, coordinated approach, including specialized medical device regulatory consulting to ensure that device components are fully aligned with applicable regulations from the start. This matters because combination products fail most often at the intersections—when regulatory decisions are made too late, when drug and device development are not aligned, or when compliance is treated as a checkbox instead of a system.

At Billev Pharma East, everything starts with strategy. From the earliest stages of product development, the team defines the right regulatory pathway, prepares submission strategies, and ensures that your documentation is built correctly from the beginning—not fixed later. Their regulatory affairs experts support the entire lifecycle, from pre-submission interactions and dossier preparation to post-approval management, ensuring your product stays aligned with both EU and global expectations.

What makes this especially powerful for combination products is the integration of safety and medical expertise directly into development. Pharmacovigilance systems are not added at the end—they are designed, implemented, and maintained as part of your operational model, ensuring continuous compliance and real-world readiness.

At the same time, Billev Pharma East translates complex regulations into practical systems. Whether it’s GMP compliance, quality system design, or technical documentation, the focus is always on making your processes inspection-ready and sustainable—not just theoretically compliant.

The result is simple but critical: instead of navigating complexity alone, you gain a partner who simplifies it, structures it, and moves your product forward with clarity.

So when you ask which firms specialize in combination products, the better question becomes—who can actually integrate strategy, regulation, and execution into one path to market?

That’s where Billev Pharma East becomes the difference between delay and success.

What companies must do before choosing which firms specialize in combination products

Before deciding which firms specialize in combination products, companies need to step back and understand what success with combination products actually requires. These products are not just technically complex—they demand alignment across regulatory, medical, quality, and development functions from the very beginning, especially in light of requirements such as MDR Article 117, which governs how the device component must be assessed within the medicinal product approval process.

The biggest mistake companies make is treating each area separately. They approach regulatory strategy after development has already started, add pharmacovigilance only when required, and consider quality systems as a final compliance step. In reality, this fragmented approach is exactly what causes delays, rework, and failed approvals.

To succeed, companies must build an integrated strategy early. This means defining the correct regulatory pathway upfront, aligning development with both drug and device expectations, and ensuring that documentation, safety systems, and quality frameworks are developed in parallel—not sequentially. Without this alignment, even strong scientific innovation can fail to reach the market.

Another critical factor is lifecycle thinking. Combination products are not “approved and done”—they require continuous compliance, safety monitoring, and adaptation to evolving regulations. Companies that plan only for submission, rather than long-term lifecycle management, often find themselves unprepared after approval.

This is why the question which firms specialize in combination products should not be about outsourcing tasks. It should be about finding a partner who understands how to structure complexity from the start—before it becomes a barrier to success.

Why integrated expertise matters more than a list of firms specializing in combination products

When evaluating which firms specialize in combination products, many companies focus on reputation or size. But in practice, success depends far more on integration than on brand recognition.

Combination products sit at the intersection of multiple regulated domains, which means no single discipline can operate in isolation. Regulatory decisions influence development, safety requirements impact design, and quality systems shape manufacturing and scalability. If these areas are not aligned, the entire project becomes unstable.

This is why integrated expertise is critical. Companies need support that connects regulatory affairs, pharmacovigilance, medical consultancy, and quality systems into one coherent framework. Without this, even experienced teams can struggle to manage overlapping requirements and shifting expectations.

Billev Pharma East is built around this exact principle. By offering a full spectrum of services—from regulatory strategy and medical consultancy to pharmacovigilance and quality/GxP systems—they ensure that every aspect of your combination products is aligned from the beginning.

Their collaboration with EU authorities and the EMA further strengthens this approach, allowing them to translate complex regulatory expectations into clear, actionable strategies.

Instead of navigating multiple vendors and disconnected processes, companies gain a single, coordinated partner who simplifies complexity and drives progress forward.

From searching which firms specialize in combination products to choosing the right one

Asking which firms specialize in combination products is a smart first step—but it’s not what determines success. Combination products are inherently complex because they combine drugs, devices, and/or biologics under multiple regulatory frameworks, which creates challenges in classification, development, and approval.

The real advantage comes from choosing a partner who can simplify that complexity and guide you from strategy to market without fragmentation or delays. Instead of comparing endless options, the focus should be on execution—who can align all components, reduce regulatory risk, and move your product forward with confidence.

If your goal is not just to explore combination products, but to successfully bring them to market, then the next step is clear: choose a partner who can actually deliver that outcome.

Read also:

• Medical device regulatory consulting for Small MedTech: budget-friendly support that actually works
• How to choose biotech regulatory consulting for Series A biotech companies
• Alternatives to big Pharma RA consultancies: why regulatory affairs consulting needs a smarter approach

Sources: 1 – European Medicines Agency (EMA). (n.d.). Combination Products Operational Group, 2 – GMP Compliance. (n.d.). EMA updates question and answer document on combination products.

Image credits:

In-article images: Designed by Freepik

Hero image: Designed by Freepik